Liquidia

Liquidia Corporation (NASDAQ: LQDA) is a biopharmaceutical company focused on the development and commercialization of inhaled therapies for cardiopulmonary disease, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its proprietary PRINT technology produces drug particles of uniform size and shape engineered for deep-lung deposition, and underpins YUTREPIA, its inhaled treprostinil dry powder product. Liquidia is also developing L606, a sustained-release liposomal treprostinil inhalation suspension partnered with Pharmosa Biopharm. Liquidia publishes no public developer portal, API, or machine-readable interface; this profile is catalogued for network identity, corporate transparency, and domain-security coverage only.

Liquidia is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Pharmaceuticals, Life Sciences, and Healthcare.

Liquidia’s developer surface includes support and 18 more developer resources.

🌐 Visit website 📡 Source on GitHub

14.6/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiopharmaceuticalPharmaceuticalsLife SciencesHealthcareDrug DeliveryPulmonary HypertensionClinical TrialsInhaled Therapeutics

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 14.6/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.9 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/liquidia: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 3

Status, limits, changes, and where to get help

Contact

Contact

Support

Support

PressReleases

PressReleases

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 5

The organization behind the API

Website

About

BlogRSS

Investors

Careers

Other 7

Properties that don't map to a standard resource type

CookiePolicy

Accessibility

EventsRSS

SECFilingsRSS

Products

Technology

CorporateSocialResponsibility

CorporateSocialResponsibility

Scroll for all 7

Source (apis.yml)

aid: liquidia
name: Liquidia
description: 'Liquidia Corporation (NASDAQ: LQDA) is a biopharmaceutical company focused on the development and commercialization
  of inhaled therapies for cardiopulmonary disease, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension
  associated with interstitial lung disease (PH-ILD). Its proprietary PRINT technology produces drug particles of uniform
  size and shape engineered for deep-lung deposition, and underpins YUTREPIA, its inhaled treprostinil dry powder product.
  Liquidia is also developing L606, a sustained-release liposomal treprostinil inhalation suspension partnered with Pharmosa
  Biopharm. Liquidia publishes no public developer portal, API, or machine-readable interface; this profile is catalogued
  for network identity, corporate transparency, and domain-security coverage only.'
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://www.liquidia.com/sites/g/files/knoqqb101156/themes/site/client_site_301/dist/images/liquidia-logo-full.svg
url: https://raw.githubusercontent.com/api-evangelist/liquidia/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: profile
x-tier-reason: no-public-api-surface
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biopharmaceutical
- Pharmaceuticals
- Life Sciences
- Healthcare
- Drug Delivery
- Pulmonary Hypertension
- Clinical Trials
- Inhaled Therapeutics
apis: []
common:
- type: DomainSecurity
  url: security/liquidia-domain-security.yml
- type: Website
  url: https://www.liquidia.com/
- type: About
  url: https://www.liquidia.com/about-us
- type: Contact
  url: https://www.liquidia.com/contact-us
- type: Support
  url: https://www.liquidia.com/contact-us
- type: PrivacyPolicy
  url: https://www.liquidia.com/privacy
- type: TermsOfService
  url: https://www.liquidia.com/legal
- type: CookiePolicy
  url: https://www.liquidia.com/cookies
- type: Accessibility
  url: https://www.liquidia.com/accessibility
- type: PressReleases
  url: https://www.liquidia.com/investors/press-releases
- type: BlogRSS
  url: https://www.liquidia.com/rss/news-releases.xml
- type: EventsRSS
  url: https://www.liquidia.com/rss/events.xml
- type: SECFilingsRSS
  url: https://www.liquidia.com/rss/sec-filings.xml
- type: Investors
  url: https://www.liquidia.com/investors/overview
- type: Careers
  url: https://liquidia.careers.hibob.com/
- type: Products
  url: https://www.liquidia.com/pipeline-and-products
- type: Technology
  url: https://www.liquidia.com/technology
- type: CorporateSocialResponsibility
  url: https://csr.liquidia.com/en/
- type: LLMsTxt
  url: llms/liquidia-llms.txt
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence